Domov › Rak dojke › Missouri › Kansas City
Klinične študije za Rak dojke v Kansas City, MO
34 študij za Rak dojke išče udeležence na lokacijah v Kansas City in okolici (v razdalji približno 30 milj). Odprite študijo, da vidite, kdo lahko sodeluje in kako kontaktirati ekipo.
Uradno besedilo študije (angleško)
Iščete udeležence za študijo? Predstavite jo na vrhu te strani — $99 za 30 dni →
The Vanguard Study: Testing a New Way to Screen for Cancer
Vključevanje udeležencevVabljeni zdravi prostovoljci
- Saint Luke's Hospital of Kansas City, Kansas City
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
Vključevanje udeležencevFaza 3
- University of Kansas Cancer Center, Westwood · 5 mi stran
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
Vključevanje udeležencevFaza 3
- HCA Midwest Division, Kansas City
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Vključevanje udeležencevOpazovalna študijaVabljeni zdravi prostovoljci
- Kansas City Veterans Affairs Medical Center, Kansas City
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
Vključevanje udeležencevFaza 2
- Saint Luke's Cancer Institute, Kansas City
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Vključevanje udeležencevFaza 1
- St. Lukes Hospital of Kansas City, Kansas City
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Vključevanje udeležencevFaza 3
- Saint Luke's Cancer Institute ( Site 0027), Kansas City
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
Vključevanje udeležencevFaza 3
- The University of Kansas Cancer Center, Westwood · 5 mi stran
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Vključevanje udeležencevFaza 3
- Saint Luke's Cancer Institute ( Site 0059), Kansas City
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
Vključevanje udeležencevFaza 3
- Clinical Trial Site, Kansas City
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Vključevanje udeležencevFaza 3
- Saint Luke's Cancer Institute, Kansas City
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
Vključevanje udeležencevFaza 1/2
- Saint Luke's Hospital of Kansas City, Kansas City
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
Vključevanje udeležencevFaza 3
- Saint Luke's Hospital of Kansas City, Kansas City
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Vključevanje udeležencevFaza 1
- Saint Luke's Cancer Institute, Kansas City
To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer
Vključevanje udeležencevFaza 2
- HCA Midwest Division, Kansas City
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Vključevanje udeležencevFaza 3
- HCA Midwest Health, Kansas City
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Vključevanje udeležencevFaza 3
- University Health Truman Medical Center, Kansas City
- University of Kansas Cancer Center - Briarcliff, Kansas City
- University of Kansas Cancer Center - North, Kansas City
- in še 1
Triple Negative Breast Cancer and Germline Hereditary Breast and Ovarian Cancer Mutation Carrier Registry
Vključevanje udeležencevOpazovalna študijaVabljeni zdravi prostovoljci
- Universtiy Health, Kansas City
- KCCC South, Kansas City
- Research Medical Center, Kansas City
- in še 2
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
Vključevanje udeležencevFaza 3
- University of Kansas Cancer Center - North, Kansas City
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Vključevanje udeležencevFaza 2/3
- Saint Luke's Cancer Institute, Kansas City
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Vključevanje udeležencevFaza 1/2
- University of Kansas Medical Center (KUMC), Westwood · 5 mi stran
HER2-positive Breast Cancer Registry
Vključevanje udeležencevOpazovalna študija
- The University of Kansas Cancer Center, Westwood · 5 mi stran
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Vključevanje udeležencevFaza 1/2
- Saint Luke's Cancer Institute, Kansas City
Integrated Cancer Repository for Cancer Research
Vključevanje udeležencevOpazovalna študijaVabljeni zdravi prostovoljci
- Saint Luke's Cancer Institute, East, Kansas City
- Saint Luke's Cancer Institute, Kansas City
- Saint Luke's Cancer Institute, Kansas City North, Kansas City
- in še 1
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
Vključevanje udeležencevFaza 3
- Saint Luke's Cancer Institute, Kansas City
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
Vključevanje udeležencevFaza 3
- Saint Luke's Cancer Institute, Kansas City
- The University of Kansas Cancer Center, Westwood · 5 mi stran
Trial of Neoadjuvant THP vs TCHP for HER2-Amplified/Positive Breast Cancer
Vključevanje udeležencevFaza 2
- The University of Kansas Cancer Center - North, Kansas City
- KUCC - Briarcliff, Westwood · 5 mi stran
- KUCC - Olathe, Westwood · 5 mi stran
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
Vključevanje udeležencevFaza 3
- Saint Luke's Hospital of Kansas City, Kansas City
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Vključevanje udeležencevFaza 3
- University of Kansas Cancer Center - Briarcliff, Kansas City
- University of Kansas Cancer Center - North, Kansas City
- University of Kansas Cancer Center at North Kansas City Hospital, North Kansas City · 2 mi stran
- in še 1
Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis
Vključevanje udeležencevFaza 1/2
- The University of Kansas Cancer Center, Westwood · 5 mi stran
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Vključevanje udeležencevOpazovalna študija
- University Health Truman Medical Center, Kansas City
- University of Kansas Cancer Center - Briarcliff, Kansas City
- University of Kansas Cancer Center - North, Kansas City
- in še 1
EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
Vključevanje udeležencevOpazovalna študija
- Saint Luke's Hospital of Kansas City, Kansas City
- University of Kansas Cancer Center, Westwood · 5 mi stran
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Vključevanje udeležencevOpazovalna študija
- Massive Bio SYNERGY-AI site, Kansas City
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
Vključevanje udeležencevFaza 3
- Truman Medical Centers, Kansas City
- University of Kansas Cancer Center - North, Kansas City
- University of Kansas Cancer Center at North Kansas City Hospital, North Kansas City · 2 mi stran
- in še 1
Študije za Rak dojke v drugih mestih
- New York City, NY136 študij
- Houston, TX126 študij
- Boston, MA112 študij
- Nashville, TN81 študij
- Los Angeles, CA73 študij
- Edison, NJ68 študij
- St. Louis, MO64 študij
- Queens, NY64 študij
- Durham, NC64 študij
- Chicago, IL59 študij
- Philadelphia, PA56 študij
- Dallas, TX55 študij
Druge študije v Kansas City
- Nemalicelični pljučni rak31 študij
- Srčno popuščanje25 študij
- Rak (vse vrste)21 študij
- Rak pljuč19 študij
- Kolorektalni rak16 študij
- Metastatski rak15 študij
- Akutna mieločna levkemija15 študij
- Rak prostate14 študij
- Rak jajčnikov11 študij
- Debelost11 študij
- Sladkorna bolezen tipa 211 študij
- Srčno-žilne bolezni11 študij
Vir: ClinicalTrials.gov, podatki pridobljeni 6. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.